Introduction
============

Hepatocellular carcinoma (HCC) is a globally prevalent malignant tumor that represents the fifth most common newly-diagnosed cancer, and the second most common cause of mortality, and HCC-related morbidity is rising rapidly [@B1]-[@B3]. Although, radical excision is the established therapeutic strategy for HCC, the rates of both recurrence and metastasis after resection remain high, and the prognosis remains poor. To the best of our knowledge, the prognosis of HCC patients after curative resection depends not only on the clinical stage of the tumor at operation, but also on the degree to which liver function is affected [@B4], [@B5]. These factors make it very difficult to predict the prognosis of HCC patients.

The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used and complete evaluation system for therapeutic allocation, as well as prognostic stratification [@B6], [@B7]. However, evidence has shown that the BCLC is relatively limited to the advanced stages of patients with HCC, while the Cancer Liver Italian Program (CLIP) was validated to be more appropriate to patients with early to advanced HCC [@B8]. A research study carried out by Camma et al. reported that the CLIP system was more suitable for predicting prognosis in advanced untreated patients, while the BCLC outperformed the CLIP system for predictions in early stage patients under treatment [@B9]. Another study suggested that there was no widely used prognostic scoring systems for HCC because of intergroup heterogeneity [@B10]. Furthermore, many staging systems are rarely used in clinical practice because they are complex and cumbersome. Consequently, there is an urgent need to develop a reliable and convenient index for routine clinical practice.

Inflammation has been reported to be involved in the pathogenesis and progression of cancer, particularly in HCC patients with a background of chronic inflammation [@B11], [@B12]. A variety of inflammation response indices, including C-reactive protein (CRP) [@B13], fibrinogen [@B14], neutrophil to lymphocyte ratio (NLR) [@B15],[@B16], Glasgow Prognostic Score (GPS) [@B17], Inflammation based score (IBS) [@B18] and Inflammation based index (IBI) [@B19], have been reported to represent useful prognostic markers for certain types of cancers, including HCC. Recently, FC scores, which incorporate preoperative plasma fibrinogen and CRP levels, were suggested to represent a prognostic marker in patients with esophageal squamous cell carcinoma [@B20]. However, there is a distinct lack of reports relating to FC scores for patients with HCC. In the present study, we aimed to investigate the prognostic predictive value of FC scores in patients with HCC, and compared the prognostic ability between FC scores and commonly-used evaluation systems.

Materials and Methods
=====================

Patients
--------

This study involved 768 consecutive patients, who were diagnosed and underwent curative resection in Zhongshan Hospital of Fudan University between December 2010 and June 2012. Patients were randomly divided into two independent cohorts at a ratio of 4:1, including a training cohort (616 patients) and a validating cohort (152 patients). The inclusion and exclusion criteria in the study were as follows: (1) no history of preoperative anticancer therapy, (2) exact pathological diagnosis of HCC, (3) radical resection of the tumor without residual cancer with the cut surface being free of cancer by histological examination were defined as radical excision, (4) with complete clinicopathological characteristics and follow-up data, (5) without any evidence of extrahepatic metastasis or other organs with primary cancer. The study\'s protocol was approved by the Clinical Research Ethic Committee of Zhongshan Hospital and all parents provided informed consent.

Laboratory Measurements
-----------------------

Preoperative serum sample were collected in tubes without the influence of any treatment. Fibrinogen level was measured by a clotting assay (Dade Thrombin Reagent, Siemens Healthcare Diagnostic Products GmbH, Germany) and carried out on an Automated Blood Coagulation Analyzer (CA-700 Sysmex Cooperation Japan) according to the manufacturer\'s instruction. And the normal reference range was defined as being between 200 and 400 mg/dl. C-reactive protein (CRP) was detected by a Vitros 5.1 FS automatic biochemical analyzer (Johnson & Johnson, New Brunswick, NJ, USA). And the normal reference scope for CRP range from 0.8 to 8 mg/L.

Follow-up
---------

The exact follow-up procedure was described in our previous study [@B21]. Computed tomography (CT) as well as magnetic resonance imaging (MRI) were applied for further examination whenever there was a sign of intrahepatic recurrence or distal metastasis. The recurrence free survival (RFS) and overall survival (OS) times were calculated from surgery to the date of the first recurrence and death, respectively. For patients without any sign of an RFS/OS event, the final follow-up data were recorded as their terminal record.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS version 21, and the Mann-Whitney U test was used to compare two independent groups. Associations between variables were analyzed using the Pearson\'s chi-squared test. Survival curves were developed using the Kaplan-Meier method and comparisons carried out using the log-rank test. Univariate and multivariate analyses for independent prognostic factors were carried out using the Cox proportional hazard model. The optimal cut-off values for fibrinogen were determined using X-tile version 3.6.1 (Yale University, New Haven, CT, USA). A nomogram was then formulated based on the results from the multivariate analysis, and a C-index and calibration curve were generated to evaluate the discriminatory ability of each scoring system. Both the nomogram and the C-index were completed with R version 3.0.2.

Results
=======

Patient Demographics
--------------------

This study involved a final cohort of 768 patients. Of these, 616 patients were classified into the training group, while 152 patients were classified into the validation group. The detailed demographics of both cohorts are shown in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. There were no significant differences between the two cohorts in terms of clinical characteristics except for ALB and IBI. By the final follow up date, on the 20^th^ December 2016, 115 patients had died. The median follow-up time was 48 months (range, 2-66 months), and the 1-, 3-, and 5-year OS were 95.3%, 78.8%, and 67.4%, respectively. The 1-, 2-, and 3-year FRS were 83.7, 56.6%, and 41.9%, respectively.

FC-scores, and the relationship between FC-score and Clinical Characteristics
-----------------------------------------------------------------------------

The optimal cutoff value for fibrinogen was 266 mg/dL, and was determined by X-tile. Thus, patients with both low fibrinogen (\<266 mg/dL) and CRP (\<10 mg/L) were allocated a score of 0. Patients exhibiting only one of these abnormalities were given a score of 1, whilst those with both abnormal CRP and fibrinogen were given a score of 2. Further analysis showed that serum AFP (p=0.029), TBI (p=0.05), GGT (p\<0.001), ALB (P=0.001), PLT (p\<0.001), along with the presence of hepatic cirrhosis (p\<0.001), tumor thrombus (p\<0.001) and MVI (p\<0.001), were found to be significantly positively associated with a high FC-score. Moreover, a high FC-score was significantly associated with advanced BCLC staging system (P\<0.001), CLIP scores (p\<0.001) and high levels of IBI, IBS, GPS (Table [2](#T2){ref-type="table"}).

Prognostic and Recurrence Factors for Patients with HCC in the training cohort
------------------------------------------------------------------------------

Univariate analysis showed that FC-score was a significant prognostic indicator (Fig. [1](#F1){ref-type="fig"} A, B and Supplementary table [S1](#SM0){ref-type="supplementary-material"}). Multivariate analysis further showed that FC-score (HR=2.21, p\<0.001), elevated preoperative serum AFP (HR=1.690, p=0.008), IBS (HR=2.01, p\<0.001), and cancer-associated characteristics including multiple tumors (HR=1.76, p=0.004), the presence of tumor thrombus (HR=2.262, p\<0.001) and microvascular invasion (HR=1.93, p=0.003), the BCLC staging system (HR=2.23, p\<0.001), and CLIP (HR=2.720, p\<0.001) were all significant independent prognostic factors for OS. Meanwhile, FC-score (HR=1.36, p\<0.001), IBS (HR=1.59, p\<0.001), multiple tumors (HR=1.49, p=0.012), the presence of tumor thrombus (HR=2.089, p\<0.001) and MVI (HR=1.388, p=0.022), the BCLC staging system (HR=1.713, p=0.003), and CLIP (HR=1.460, p=0.04) were found to be poor indicators of RFS (Table [3](#T3){ref-type="table"}).

In further subgroup analysis, FC-score was proven to represent a prominent prognostic factor for both OS and RFS (p\<0.05) (Fig. [1](#F1){ref-type="fig"} E-H).

Comparison of Predictive accuracy between FC-score and other Predictive Models
------------------------------------------------------------------------------

The C-index of the FC-score for OS and RFS (0.698 and 0.594, respectively) accounted for the third, only second to CLIP (0.724 and 0.622, respectively) and BCLC (0.721 and 0.629, respectively), and was superior to that of other inflammation-based prognostic scores, including IBI (0.612 and 0.539, respectively), IBS (0.675 and 0.576, respectively), and GPS (0.629 and 0.542, respectively) (Table [4](#T4){ref-type="table"}).

Validation of Prognostic Analysis in the validation cohort
----------------------------------------------------------

In the validation cohort, univariate analysis showed that the FC-score was a significant prognostic indicator (Fig. [1](#F1){ref-type="fig"} C, D and Supplementary table [S1](#SM0){ref-type="supplementary-material"}). Additionally, FC-score (HR=2.862 for OS; HR=1.865 for RFS) was an independent prognostic indicator for both OS and RFS in the multivariate analysis, which was consistent with results for the training cohort (Table [3](#T3){ref-type="table"})*.* Furthermore, C-index of the FC-score system improved to a new state of 0.701 and 0.624 for OS and RFS, respectively (Table [4](#T4){ref-type="table"}).

A New Nomogram for Survival Prediction that integrates FC-score into the Routine Clinical Staging System
--------------------------------------------------------------------------------------------------------

We developed a novel nomogram that integrated the FC-score into the BCLC staging system for both OS and RFS (Fig. [2](#F2){ref-type="fig"} A,B). The calibration curves, which represent an internal validation system, for the nomogram are shown in Fig. [2](#F2){ref-type="fig"} C-F. The calibration plots show high concordance between prediction and actual observations for 3-year, 5-year OS and 1-year, 3-year RFS.

The novel nomogram showed better predictive accuracy (C-index, 0.746 and 0.654 for OS and RFS, respectively) than the BCLC staging system (C-index, 0.721 and 0.629 for OS and RFS, respectively) and the FC-score alone (C-index, 0.698 and 0.594 for OS and RFS, respectively) (Table [4](#T4){ref-type="table"}).

Validations of the Prediction Ability of the Nomogram for Survival
------------------------------------------------------------------

In the validation cohort, the C-indexes of the novel nomogram for OS and RFS were 0.779 and 0.669, respectively, which were superior to that of the BCLC system alone (0.729 and 0.634, individually) and FC-score (0.701 and 0.624, individually) (Table [4](#T4){ref-type="table"}). Furthermore, the calibration curve of the well-constructed nomogram fitted well in terms of prediction and observation (Supplementary Fig. [S1](#SM0){ref-type="supplementary-material"} A-D).

Comparison of the Nomogram and BCLC Stages by Decision Curve Analysis
---------------------------------------------------------------------

The decision curve analysis represents a novel method to evaluate the net clinical benefit of predictive models [@B22]. Our nomogram showed better net benefits with a wider range of threshold probability than either the BCLC or FC-score alone in terms of both OS and RFS by decision curve analysis in the training cohort (Fig. [2](#F2){ref-type="fig"} G-I). Also, it fitted well at 2-year, 3-year OS and 2-year RFS in the validation cohort (Supplementary Fig.[S1](#SM0){ref-type="supplementary-material"} E-G).

Discussion
==========

In this study, we have developed a novel, effective and convenient predictive FC-score system, based on the levels of fibrinogen and CRP. Additionally, we created a new nomogram, incorporating the FC-score system into the BCLC staging system, which exhibited higher discrimination ability and was evaluated by calibration curve and decision curve analysis in two independent cohorts.

Multiple researches have focused on the prominent roles of fibrinogen and CRP in the prognostic prediction [@B23]-[@B28].However, in the researches by Zhang X et al and Xiao-Hui Li et al, the value of serum fibrinogen was only researched in the training cohort thus absenting the validation study[@B23], [@B24]. The main advantages of the current study were that a relatively large HCC population who underwent curative resection was involved, and the findings in the training cohort were further verified in the validation cohort. Furthermore, nomograms which could give an individualized risk assessment for each patient were constructed, and the reliable evaluation index (C-index) was applied to assess the discrimination ability among the routine clinical prediction indexes. Not only calibration curve but also decision curve analysis was used to evaluated the prediction accuracy and clinical net benefit of our nomogram in the two independent cohorts, which could enhance the reliability and value of our research. Furthermore, the combination of CRP and fibrinogen was found to be more powerful prediction index than CRP and fibrinogen individually.

To the best of our knowledge, inflammation has been reported to be a key factor in the pathogenesis of tumors, and plays a prominent role in the development and metastasis of cancer, particularly in HCC, which would develop from a heavy chronic liver inflammatory disease [@B2], [@B11], [@B12]. Fibrinogen, which is synthesized by hepatocytes, plays a key role in activating the coagulation cascade [@B29]. Furthermore, a mounting number of research studies have demonstrated the prominent role of fibrinogen in the regulation of the inflammatory response. Previously, fibrinogen was reported to represent a pro-inflammatory factor for stroke and vascular disease [@B30]-[@B32]. Via the interaction of a ligand-receptor mechanism involving a wide range of immune cells such as monocytes and microphages, fibrinogen also plays a key role in regulating reactions within the inflammation cascade [@B30], [@B33]. Furthermore, the prominent role of fibrinogen in predicting prognosis has been reported in a large number of cancers, including HCC, advanced esophageal squamous cell carcinoma, renal cell carcinoma, and esophageal squamous cell carcinoma [@B23], [@B24], [@B34]-[@B37]. CRP, which is another prominent system inflammation response factor, has been reported to be closely associated with prognosis in HCC, pancreatic cancer, renal cancer, gastric cancer, lung cancer and lymphoma [@B26]-[@B27], [@B38]-[@B41]. Also, there were a systematic review and meta-analysis shown that high level of CRP and CRP/albumin were associated with poor survival [@B25], [@B28]. Therefore, it is reasonable to incorporate fibrinogen and CRP to establish the FC-score.

Previously, CRP and fibrinogen were used to predict the occurrence of cardiac-cerebral vascular disease [@B42], [@B43]. While the FC-score was first reported to represent a significant predictor in patients with esophageal squamous cell carcinoma, our study represents a new contribution to HCC research [@B20]. In our present research, FC-score was shown to be an independent prognostic variate. Patients with a high score on the FC-scoring system appear to be more likely to suffer from a poor prognosis and a high rate of recurrence. Besides, we also investigated the predictive ability of FC-scoring, and found that its efficiency and accuracy were superior to other routinely-used inflammatory based systems such as IBI, IBS, and GPS in terms of C-index. To investigate the common applicability of this scoring system across different groups of patients, we also conducted subgroup analysis and found that FC-score was indicated as a predictive factor for patients classified by hepatic cirrhosis and tumor thrombus. In the correlation analysis, FC-score was effective in relation to a wide variety of factors: tumor capsule; differentiation; tumor thrombus; AFP level; tumor number; and tumor size. Consequently, FC-score can be widely used as a predictor across many different subgroups of patients.

Routine clinical predictive systems, such as the BCLC and CLIP, unfortunately lack the involvement of an inflammatory index [@B6], [@B44], [@B45]. Also, these traditional systems lack flexibility for the heterogeneity of the tumor. The nomogram, which provides a more individualized prediction, is a statistical model based on a combination of variables. Until now, many nomograms have been established for a range of different types of cancer and have shown superior prediction [@B46]-[@B48]. Therefore, we developed new nomograms that integrated FC-score with BCLC for both OS and RFS, thus creating a much stronger predictor for individual patients. Interestingly, improvements in the predictive ability for both OS and RFS were observed with FC-scores or the BCLC alone, which was validated in the validation group. Our present research, together with findings from our previous studies, supported the prominent role of inflammation in prognostic prediction [@B18]. Consequently, our findings suggest that the FC-scoring system, with its wide range of applications, is a very reliable and convenient predictive system.

Several limitations need to be considered in our present study. Firstly, this was a retrospective study in a single institution in China. Secondly, this study only focused on patients undergoing curative resection. Finally, whether our new nomogram can be applied to patients who receive treatment other than curative resection remains to be determined. Hence, it is important to carry out a multicenter study and enroll a large number of patients with advanced clinical stages and different therapy strategies in the future.

Conclusions
===========

In conclusion, FC-score represents a novel, convenient, reliable, and accurate prognostic predictor for both OS and RFS in patients with HCC undergoing curative resection. The newly developed nomogram gives rise to better discrimination ability for individual prediction.

Supplementary Material {#SM0}
======================

###### 

Table S1 and Figure S1.

###### 

Click here for additional data file.

This work was supported by National Key Sci-Tech Special Project of China (Grant No. 2012ZX10002010-001/002); the National Natural Science Foundation of China (Grant Nos. 81302102); Research Programs of Science and Technology Commission Foundation of Shanghai (Grant No. 13CG04, 16DZ0500300).

![Kaplan-Meier survival curves for patients in the research by FC-score. overall survival (AC) and recurrence free survival (BD) in training cohort and validation cohort respectively. Furthermore, in the subgroup analysis for OS, E survival curve for patients in the subgroup with tumor thrombus, F survival curve for patients without tumor thrombus. G survival curve for patients in the subgroup with hepatic cirrhosis, H for patients without hepatic cirrhosis. FC-score=fibrinogen and C-reactive protein score.](jcav09p0148g001){#F1}

![Hepatocellular carcinoma (HCC) OS and RFS nomogram, calibration curve, and decision curve analysis in the training cohort. (A for OS and B for RFS). To use the nomogram, the value of an individual patient is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. the sum of these numbers is located on the total point axis, and a line is drawn downward to the survival axes to determine the likelihood of 1-,3-, and 5-year survival. The calibration curve for predicting OS at (C) 3 years, (D) 5 years, and predicting RFS at (E) 1 year, (F) 3 years. Nomogram-predicted probability of overall survival is plotted on the x axis and actual overall survival is plotted on the y axis. Decision curve analyses depict the clinical net benefit in pairwise comparisons across the different models. Nomogram is compared with the BCLC stage in terms of (G) 2-year, (H) 3-year OS and (I) 2-year RFS. Dashed lines indicate the net benefit of nomogram in each of the curves across a range of threshold probabilities. The horizontal solid black line represents the assumptions that no patient will experience the event, and the solid grey line represents the assumption that all patients will relapse. On decision curve analysis, nomogram showed superior net benefit compared with BCLC stage across a range of threshold probabilities. BCLC=Barcelona Clinic Liver cancer, OS=overall survival, RFS=recurrence free survival.](jcav09p0148g002){#F2}

###### 

Demographic and clinical characteristics of patients

                        training cohort   validation cohort             
  --------------------- ----------------- ------------------- --------- --
  Gender, male/femeal   514/102           131/21              0.409     
  Age, \<60/≥60         343/273           80/72               0.498     
  HBsAg,                                                                
  negative/positive     100/516           27/125              0.649     
  AFP                                                                   
  \<400/≥400 ng/mL      435/181           113/39              0.363     
  TBIL                                                                  
  \<20/≥20 µmol/L       558/58            136/16              0.678     
  GGT, \<45/≥45 U/L     248/368           63/89               0.789     
  ALT, \<50/≥50 U/L     495/121           119/33              0.569     
  ALB, \<35/≥35g/L      21/595            45/107              \<0.001   
  CRP, \<10/≥10mg/L     549/67            136/16              0.901     
  FIB,\<266/≥266mg/L    399/217           102/50              0.589     
  PLT                                                                   
  \<200/≥200 10\^9/L    509/107           124/28              0.76      
  cirrhosis,no/yes      156/460           37/115              0.802     
  tumor number,                                                         
  single/multiple       533/83            127/25              0.345     
  tumor throbus                                                         
  no/yes                577/39            143/9               0.852     
  tumor capsule                                                         
  no/yes                394/222           103/49              0.38      
  tumor size                                                            
  \<5/≥5cm              360/256           78/74               0.112     
  LNM                                                                   
  no/yes                612/4             150/2               0.403     
  MVI, no/yes           450/166           102/50              0.144     
  differentiation,                                                      
  I-II/III-IV           421/195           102/48              0.985     
  IBS, 0/1              12/551/52         39/103/10           \<0.001   
  GPS, 0/1/2            535/73/8          132/20/0            0.342     
  IBI,0/1/2             322/294           80/70               0.711     
  FC-score,0/1/2        386/176/54        97/44/11            0.832     
  BCLC, A/B/C           401/186/29        91/52/9             0.468     
  CLIP, 0/1-3/4-6       337/272/7         87/61/4             0.287     

APF, alpha fetal protein; FIB, fibrinogen; PLT, platelet; LNM, lymph node metastasis; MVI, microvascular invasion; IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.

###### 

The correlation between clinicopathologic characters and FIB and FC-score (training cohort)

  Characters             FC-score                         
  ---------------------- ----------- ---------- --------- ---------
  all patients           386         176        54        
  Gender, male/female    66/320      30/146     6/48      0.53
  Age, \<60/≥60          220/166     89/87      34/20     0.193
  HBsAg,                                                  
  negative/positive      53/333      40/136     7/47      0.022
  AFP                                                     
  \<400/≥400 ng/mL       282/104     123/53     30/24     0.029
  TBIL                                                    
  \<20/≥20 µmol/L        352/34      162/14     44/10     0.05
  GGT, \<45/≥45 U/L      178/208     61/115     9/45      \<0.001
  ALT, \<50/≥50 U/L      304/82      148/28     43/11     0.333
  ALB, \<35/≥35g/L       12/374      3/173      6/48      0.003
  CRP, \<10/≥10mg/L      386/0       163/13     0/54      \<0.001
  PLT                                                     
  \<200/≥200 10\^9/L     341/45      136/40     32/22     \<0.001
  N,\<6.3/≥6.3 10\^9/L   353/33      161/15     38/16     \<0.001
  L,\<3.2/≥3.2 10\^9/L   371/15      160/16     49/5      0.027
  M,\<0.6/≥0.6 10\^9/L   311/75      114/62     14/40     \<0.001
  cirrhosis,no/yes       72/314      61/115     23/31     \<0.001
  tumor number,                                           
  single/multiple        340/46      144/32     49/5      0.083
  tumor throbus                                           
  no/yes                 373/13      162/14     42/12     \<0.001
  tumor capsule                                           
  no/yes                 260/126     103/73     31/23     0.074
  tumor size                                              
  \<5/≥5cm               266/120     83/93      11/43     \<0.001
  LNM                                                     
  no/yes                 384/2       176/0      52/2      0.011
  MVI, no/yes            303/83      120/56     27/27     \<0.001
  differentiation,                                        
  I-II/III-IV            271/115     119/57     31/23     0.161
  IBS, 0/1               219/167     82/94      21/33     0.005
  GPS, 0/1/2             367/19/0    163/11/2   5/43/6    \<0.001
  IBI,0/1/2              12/374/0    1/166/89   0/11/43   \<0.001
  FC-score,0/1/2                                          
  BCLC, A/B/C            301/74/11   93/72/12   8/40/6    \<0.001
  CLIP, 0/1-3/4-6        235/150/1   85/90/1    17/32/5   \<0.001

APF, alpha fetal protein; FIB, fibrinogen; PLT, platelet; LNM, lymph node metastasis; MVI, microvascular invasion; IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.

###### 

Multivariate analyses for OS and RFS in HCC patients.

                           training cohort                       validation cohort                                                                                     
  ------------------------ ----------------- ------------------- ------------------- ------------------ ------- ----------------- ------------------ ----------------- ------------------
  AFP, \<400/≥400 ng/mL                                                                                         0.008             1.690(1.14-2.49)                     
  single/multiple                                                                                               0.004             1.768(1.11-2.82)   0.012             1.49(1.09-2.05)
  tumor throbus, no/yes    0.03              2.091(1.59-7.41)    0.032               2.428(1.75-4.44)           \<0.001           2.262(1.32-3.88)   \<0.001           2.089(1.38-3.15)
  Lymph node metastasis,                                                                                                                                               
  no/yes                   0.017             8.466(1.46-48.91)                                                                                                         
  MVI, no/yes              0.044             2.298(1.86-6.09)    0.037               1.802(1.13-2.75)           0.003             1.93(1.26-2.96)    0.022             1.388(1.05-1.84)
  IBS, 0/1                 0.01              3.036(2.92-6.96)    0.015               1.912(1.14-3.22)   0.001   2.01(1.32-3.03)   \<0.001            1.59(1.25-2.02)   
  GPS, 0/1/2                                                                                                                                                           
  IBI,0/1/2                0.05              2.989(0.98-9.09)    0.036               2.054(1.05-4.03)                                                                  
  FC-score,0/1/2           0.008             2.862(1.31-6.26)    0.023               1.865(1.09-3.19)           \<0.001           2.21(1.48-3.26)    0.012             1.36(1.07-1.73)
  BCLC, A/B/C              0.024             2.173(1.11-4.26)    0.016               1.712(1.11-2.65)           \<0.001           2.23(1.63-3.06)    0.003             1.713(1.19-2.45)
  CLIP, 0/1-3/4-6          \<0.001           7.956(3.41-18.58)   0.004               1.967(1.24-3.11)           \<0.001           2.72(1.76-4.21)    0.04              1.46(1.02-2.09)

APF, alpha fetal protein; MVI, microvascular invasion; IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.

###### 

Ranking of clinical staging system using C-index for OS and RFS

                        Training cohort                 Validation cohort                                                  
  --------------------- ----------------- ------------- ------------------- ------------- -- ------- ------------- ------- -------------
  nomogram              0.746             0.743-0.749   0.654               0.652-0.656      0.774   0.771-0.777   0.669   0.666-0.672
  BCLC                  0.721             0.718-0.724   0.629               0.627-0.631      0.729   0.726-0.723   0.634   0.631-0.631
  CLIP                  0.724             0.721-0.727   0.622               0.620-0.624      0.738   0.735-0.741   0.631   0.628-0.634
  FC-score              0.698             0.695-0.701   0.594               0.592-0.596      0.701   0.698-0.704   0.624   0.621-0.627
  IBS                   0.675             0.672-0.678   0.576               0.574-0.678      0.709   0.706-0.712   0.611   0.608-0.614
  GPS                   0.629             0.626-0.631   0.542               0.540-0.544      0.594   0.591-0.593   0.532   0.529-0.535
  IBI                   0.612             0.609-0.615   0.539               0.537-0.541      0.657   0.654-0.660   0.615   0.612-0.618
  CRP, \<10/≥10mg/L     0.614             0.611-0.617   0.553               0.551-0.555      0.624   0.621-0.627   0.566   0.563-0.569
  FIB,\<266/≥266mg/dL   0.636             0.633-0.639   0.556               0.554-0.558      0.638   0.635-0.641   0.604   0.601-0.607

IBS, Inflammation based score; GPS, Glasgow Prognostic Score; IBI, inflammation based index; FC-score, fibrinogen and C-reactive protein score; BCLC, Barcelona Clinic Liver Cancer staging system; CLIP, Cancer Liver Italian Program.
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